Texas Justice and the Industry's Image

With its $253 million judgment against Merck & Co. Inc. (reduced to $26.1 million under Texas law), the jury "sent a message" about what it perceived as the pharmaceutical industry's culture of greed. Ironically Merck's liability gives it a rare opportunity to right the ship. But will industry's tarnished image impede the approval and use of Merck's most important upcoming product, the HPV vaccine Gardasil?

It would be tough to claim that the Texas jury's decision in favor of the woman who claimed her husband was killed by rofecoxib (Vioxx) reflected medical truth. But the fact that Robert Ernst probably didn't die of a heart attack—much less one that was caused by Vioxx—was beside the point. With its $253 million judgment against Merck & Co. Inc. (reduced to $26.1 million under Texas law), the jury "sent a message" about what it perceived as the pharmaceutical industry's culture of greed.

The industry is unlikely to hear that message: its executives simply don't believe it. Too often we've heard them dismiss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.